跳转至内容
Merck
CN

SML3560

MU380

≥98% (HPLC)

别名:

(R)-6-bromo-5-(piperidin-3-yl)-3-(1-(trifluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine; 6-Bromo-5-(3R)-3-piperidinyl-3-[1-(trifluoromethyl)-1H-pyrazol-4-yl]-pyrazolo[1,5-a]pyrimidin-7-amine

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C15H15BrF3N7
化学文摘社编号:
分子量:
430.23
UNSPSC Code:
12352200
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

NC1=C(C([C@@]2([H])CNCCC2)=NC3=C(C=NN13)C4=CN(N=C4)C(F)(F)F)Br

Biochem/physiol Actions

MU380 is a metabolically stable analog of CHK1 inhibitor SCH900776 (MK8776) does not undergo in vivo N-dealkylation. MU380 is a potent and selective CHK1 inhibitor, which potently sensitizes multiple cancer cell lines to DNA antimetabolites including hydroxyurea, cytarabine and gemcitabine.
Metabolically stable, potent and selective CHK1 inhibitor


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation
Pounami Samadder, Fedor Nikulenkov, Hana Kolarova
Molecular Cancer Therapeutics, 16, 1831-1842 (2017)
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
Molecular Oncology, 14, 2487-2503 (2020)
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Haematologica, 104, 2443-2455 (2019)



全球贸易项目编号

货号GTIN
SML3560-5MG04065268091883
SML3560-25MG04065268091876